Transparency and traceability
Authors should explain which data underpin the findings, where the data came from, how they were collected or obtained, and how readers may access them or understand the reasons for restriction.
Arogya: Journal of Public Health and Health Services in Indonesia encourages transparency, traceability, and responsible reuse of research data. Data availability must always be balanced with privacy, confidentiality, consent, research ethics, third-party rights, and applicable legal requirements.
This policy applies to authors and all contributors to manuscripts submitted to Arogya. It covers primary and secondary data used to produce an article's findings, including quantitative and qualitative data, survey data, laboratory data, observational data, clinical trial data, research instruments, protocols, analysis code, and other relevant supporting materials.
The policy aims to help readers assess, verify, and—where permitted—reuse the evidence underlying research findings, while protecting the rights and safety of participants, patients, communities, data owners, and responsible institutions.
Authors should explain which data underpin the findings, where the data came from, how they were collected or obtained, and how readers may access them or understand the reasons for restriction.
Data should be shared openly when consent, ethics, privacy, rights, security, and applicable law permit. Openness must not override confidentiality or create an unacceptable risk of re-identification.
Only data necessary for the research purpose and verification of findings should be collected or shared. Direct and indirect identifiers must be protected in proportion to the risk.
Data created or collected by others must be used in accordance with permissions, data-owner terms, relevant consent, and licences. Data sources must be properly acknowledged and cited.
Arogya encourages the FAIR principles—Findable, Accessible, Interoperable, and Reusable—where appropriate to the context and required protections. FAIR does not mean that every dataset must be publicly available; access may require authentication or authorisation.
Every manuscript must include a Data Availability Statement, including when data cannot be shared or the statement is not applicable. The statement should appear in the section specified by the manuscript template or near the end of the article before the references, as instructed by the journal.
A Data Availability Statement should be concise, specific, and verifiable. When data are shared openly or through controlled access, the statement should identify:
For clinical trials covered by ICMJE policy, the data sharing statement must meet ICMJE-specific elements, including the status of sharing de-identified individual participant data, the data and documents available, the timing and duration of access, and the access criteria.
Datasets may be made publicly accessible through an appropriate repository when permissions, consent, ethics requirements, and law allow. Provide metadata, a reuse licence, and a persistent identifier where available.
Data may be accessed only by eligible applicants through a request and approval process managed by the responsible party. Conditions may include ethics approval, a data-use agreement, or a security plan.
Data must not be shared when disclosure would breach privacy, consent, law, third-party rights, security, or ethics requirements. Authors should explain the specific reason and, where possible, provide safe summaries or metadata.
Acceptable reasons for restriction may include direct or indirect re-identification risks, very small groups, sensitive health data, restrictions in consent forms or ethics protocols, confidentiality agreements, data-owner rights, or legal prohibitions. Restrictions should be proportionate and explained transparently.
When the full dataset cannot be released, authors are encouraged to provide a safe alternative, such as aggregate data, validated synthetic data that do not disclose the original records, a data dictionary, protocol, analysis code, or supervised access. Such alternatives must not be presented as equivalent to the original data.
Health data and information are classified as specific Personal Data under Indonesia's Law No. 27 of 2022 on Personal Data Protection. Medical records and patients' private health information are also protected by health-sector regulations. Accordingly, health data sharing requires particular care.
A statement that a dataset has been anonymised does not replace compliance with ethics approval, participant consent, or applicable law. Arogya may request information about data governance and safeguards when necessary to assess a manuscript.
For clinical trials that begin enrolling participants on or after 1 January 2019 and are covered by ICMJE policy, authors must include a data sharing plan in the trial registration and a data sharing statement in the manuscript. Any change to the plan after registration should be reflected in the manuscript statement and updated in the relevant registry record.
The statement must explain whether de-identified individual participant data (including data dictionaries) will be shared; which data will be shared; which supporting documents will be available; when and for how long the data will be available; and who may access the data, for which types of analyses, and through what mechanism.
Authors conducting secondary analyses must properly cite the dataset source, include a persistent identifier where available, comply with the data-use terms, and explain how their analysis differs from previous publications.
Arogya recommends institutional repositories, subject-specific repositories, or general-purpose repositories with clear governance and access conditions. Select a repository that is appropriate for the sensitivity of the dataset and institutional policy. Repository examples are not exclusive endorsements and do not mean that every dataset is suitable for deposit there.
FAIR means that data and metadata should be made findable, accessible, interoperable, and reusable. Access may still be restricted through authentication or authorisation when necessary to protect individuals and legitimate interests.
Editors may request further explanations, documentation, protocols, evidence of approval, repository information, or restricted access to underlying data to assess the consistency and reliability of a manuscript. Such requests must respect applicable ethics, privacy, rights, and legal restrictions.
Reviewers must not request or receive personal data that identify patients or participants. Data supplied for editorial assessment must be shared securely and used only for manuscript evaluation; such access does not make the data publicly available.
Suspected fabrication, falsification, manipulation, concealment of data restrictions, unauthorised data use, or a false data availability statement will be handled under Arogya's publication ethics policy and relevant guidance. Depending on the evidence and seriousness, actions may include requests for clarification, a pause in editorial decisions, manuscript rejection, correction, or appropriate post-publication action.
Use the following examples as templates and adapt them to the actual circumstances of the research. Replace all bracketed text. Do not state that data are available unless the link, permission, or access process is genuinely in place.
“The data supporting the findings of this study are openly available in [repository name] at [persistent DOI/URL]. The dataset includes [brief description of data] and may be reused under the [licence name] licence.”
“The data supporting the findings of this study are not publicly available because of [specific reason, such as participant privacy protection or ethics approval conditions]. Access requests may be submitted to [role/unit or data steward] through [official mechanism/contact]. Requests will be considered from applicants meeting [criteria], for [permitted purposes], after obtaining [ethics approval/data-use agreement/other required permission].”
“The individual-level data used in this study cannot be shared because of [specific legal, privacy, consent, or contractual reason]. This restriction is necessary to protect [relevant party or interest]. Non-identifying aggregate information is presented in the article and/or its supplementary materials.”
“Data availability is not applicable to this article because no new dataset was generated or analysed. This article uses [explain where relevant: a conceptual review, analysis of published documents, or public sources cited in the article].”
“The data analysed in this study were obtained from [data source/owner]. The authors are not permitted to redistribute or independently archive the data because of [access/licensing terms]. Access may be obtained through [official link or procedure of the data owner], subject to the owner's requirements.”
This policy has been prepared with reference to relevant international guidance and Indonesian regulations. Authors remain responsible for complying with the rules and guidance applicable when the research and publication take place.
This policy applies to all manuscripts submitted to Arogya from its effective date and may be reviewed when relevant ethical guidance, scientific standards, or applicable regulations change.
The ISSN will be updated once it has been officially assigned.
Arogya's indexing information will be updated after each journal listing or indexing status has been officially confirmed.
External resources to support manuscript preparation and reference management.
An open-access scholarly journal publishing research and academic studies in public health and health services.
Open access for readers
Published by
PT Pustaka Sosio Edukasi
Publisher Website
pustakaedukasi.com
Publication Frequency
Three issues per year: April, August, and December.
Articles are published under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) license, unless otherwise stated.